Skip to main content
SpringerLink
Log in

Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats

Naunyn-Schmiedeberg's Archives of Pharmacology volume 389, pages 1315–1324 (2016)Cite this article

Abstract

Since chronic kidney disease due to diabetic nephropathy (DN) is becoming an ever larger health burden worldwide, more effective therapies are desperately needed. In the present study, the anti-diabetic and renoprotective effects of aliskiren have been evaluated in streptozotocin (STZ)-induced DN in rats. DN was induced by a single intraperitoneal injection of STZ (65 mg/kg). Three weeks after STZ, rats were divided into four groups; normal, diabetic, diabetic treated with gliclazide (10 mg/kg/day) for 1 month, and diabetic treated with aliskiren (50 mg/kg/day) for 1 month. At the end of the experiment, mean arterial blood pressure and heart rate were recorded. Rats were then euthanized and serum was separated for determination of glucose, insulin, kidney function tests, superoxide dismutase activity (SOD), adiponectin, and tumor necrosis factor-alpha (TNF-α). One kidney was used for estimation of malondialdehyde (MDA), reduced glutathione (GSH), and nitric oxide (NO) contents. Other kidney was used for histopathological study and immunohistochemical measurement of caspase-3 and transforming growth factor beta (TGF-β). In addition, islets of Langerhans were isolated from normal rats by collagenase digestion technique for in vitro study. Aliskiren normalized STZ-induced hyperglycemia, increased insulin level both in vivo and in vitro, normalized kidney function tests and blood pressure, and alleviated STZ-induced kidney histopathological changes. This could be related to the ability of aliskiren toward preserving hemodynamic changes and alleviating oxidative stress and inflammatory and apoptotic markers induced by STZ in rats. However, aliskiren was more effective than gliclazide in relieving STZ-induced DN. These findings support the beneficial effect of aliskiren treatment in DN which could be attributed to its anti-diabetic, renoprotective, antioxidant, anti-inflammatory, and anti-apoptotic effects. Moreover, clinical studies are required to establish the effectiveness of aliskiren treatment in patients suffering from hypertension and diabetes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Abbreviations

ACEIs:

Angiotensin converted enzyme inhibitors

ARB:

Angiotensin II receptor blocker

BUN:

Blood urea nitrogen

DM:

Diabetes mellitus

DN:

Diabetic nephropathy

GSH:

Reduced glutathione

HR:

Heart rate

MDA:

Malondialdehyde

MAP:

Mean arterial pressure

NO:

Nitric oxide

PRA:

Plasma renin activity

RAAS:

Renin-angiotensin aldosterone system

ROS:

Reactive oxygen species

STZ:

Streptozotocin

SOD:

Superoxide dismutase activity

TGF-β:

Transforming growth factor-beta

TNF-α:

Tumor necrosis factor-alpha

References

  • Abassi Z, Winaver J, Feuerstein G (2009) The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol 78:933–940

    Article  CAS  PubMed  Google Scholar 

  • Abuelezz SA, Hendawy N, Osman WM (2016) Aliskiren attenuates bleomycin-induced pulmonary fibrosis in rats: focus on oxidative stress, advanced glycation end products, and matrix metalloproteinase-9. Naunyn Schmiedeberg’s Arch Pharmacol 389:897. doi:10.1007/s00210-016-1253-3

    Article  CAS  Google Scholar 

  • Akbar DH, Hagras MM, Amin HA, Khor-Shid OA (2012) Comparison between the effect of glibencla-mide and captopril on experimentally induced diabetic nephropathy in rats. J Renin-Angiotensin-Aldosterone Syst 14(2):103–115

    Article  CAS  PubMed  Google Scholar 

  • Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M (2008) Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet 33:101–106

    Article  CAS  PubMed  Google Scholar 

  • Azizi M, Bissery A, Lamarre-Cliche M, Menard J (2004) Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 43:785–790

    Article  CAS  PubMed  Google Scholar 

  • Banchroft JD, Stevens A, Turner DR (1996) Theory and practice of histological techniques, Fourth edn. Churchil Livingstone, New York , London, San Francisco, Tokyo

    Google Scholar 

  • Barzegar- Fallah A, Alimoradi H, Asadi F, et al. (2015) Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 42(4):361–368

    Article  CAS  PubMed  Google Scholar 

  • Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61:882–888

    CAS  PubMed  Google Scholar 

  • Coca SG, Ismail-Beigi F, Hag N, Krumholz HM, Parikh CR (2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus systematic review and meta-analysis. Arch Intern Med 172(10)

  • De Boer IH, Rue TC, Hall YN, et al. (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305(24):2532–2539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Mello WC (2015) Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR (mRen2)27 rats. J Renin-Angiotensin- Aldosterone Syst 16(3):488–494

    Article  CAS  PubMed  Google Scholar 

  • Desfaits AC, Serri O, Renier G (1997) Gliclazide decreases cell mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism 46:1150–1156

    Article  CAS  PubMed  Google Scholar 

  • Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, et al. (2010) Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 28:1554–1565

    Article  CAS  PubMed  Google Scholar 

  • Doulton TW (2006) ACE inhibitor-angiotensin receptor blocker combinations: a clinician’s perspective. Mini Rev Med Chem 6:491–497

    Article  CAS  PubMed  Google Scholar 

  • El Nahas AM (1992) Growth factors and glomerular sclerosis. Kidney Int 36:S15–S20

    CAS  Google Scholar 

  • Esch van JH, Moltzer E, van Veghel R, et al. (2010). Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. 28(10): 2145–55

  • Feldman DL, Liang J, Xuan H, Contrepas A, Zhou Y (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52:130–136

    Article  CAS  PubMed  Google Scholar 

  • Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M (2003) Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 41:31–36

    Article  CAS  PubMed  Google Scholar 

  • Fowler MJ (2008) Micro vascular and macro complications of diabetes clinical diabetes. Diabetes J Orgvol 26:277–282

    Google Scholar 

  • Gandhi S, Srinivasan BP, Akarte AS (2013) Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats. J Renin-Angiotensin-Aldosterone Syst 14(1):3–13

    Article  CAS  PubMed  Google Scholar 

  • Habibi J, Whaley-Connell A, Hayden MR, et al. (2008) Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinol 149:5643–5653

    Article  CAS  Google Scholar 

  • Hamed AT, Taha MM, Nasser LM (2013) Renoprotective effect of aliskiren monotherapy and aliskiren_pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy. Bull Fac Pharm, Cairo Univ 51:221–227

    Article  Google Scholar 

  • Huby AC, Rastaldi MP, Caron K, et al. (2009) Restoration of podo¬cyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS One 4:1–9

    Article  CAS  Google Scholar 

  • Jensen C, Herold P, Brunner HR (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7:399–410

    Article  CAS  PubMed  Google Scholar 

  • Kamal SM (2013) Aliskiren protects against hypercholesterolemia and oxidative stress on isolated aortae in cholesterol-fed rats. J Nanomed Nanotechol S5:007

    Google Scholar 

  • Kang Y S, Mi H L, Hye K S, Young Y H, Jin J C (2010). Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant. 1 of 11

  • Karcioglu SS, Palabiyik SS, Bayir Y, Karakus E, Mercantepe T, Halici Z, Albayrak A (2016) The role of RAAS inhibition by aliskiren on paracetamol-induced hepatotoxicity model in rats. J Cell Biochem 117(3):638–646

    Article  CAS  PubMed  Google Scholar 

  • Kelly DJ, Zhang Y, Moe G, et al. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50:2398–2404

    Article  CAS  PubMed  Google Scholar 

  • Kiran G, Nandini CD, Ramesh HP, Sali-math PV (2012) Progression of early phase diabetic nephropathy in streptozotocin-induced diabetic rats: evaluation of various kidney-related parameters. Indian J Exp Biol 50(2):133–140

    CAS  PubMed  Google Scholar 

  • Komers R (2013) Renin inhibition in the treatment of diabetic kidney disease. Clin Sci (Lond) 124:553–566

    Article  CAS  Google Scholar 

  • Kramer BK, Ritthaler T, Schweda F, Ittner KP, Scholz H, Riegger GA, Kurtz A (1998) Effects of the angiotensin II type-1 receptor antagonist ZD7155 on angiotensin II-mediated regulation of renin secretion and renal renin gene expression, renal vasoconstriction, and blood pressure in rats. J Cardiovasc Pharmacol 31:700–705

    Article  CAS  PubMed  Google Scholar 

  • Kumar KE, Koratana R, Putta S (2015) Effect of aqueous pericarp extract of Litchi chinensis on hypoglycemic and antihyperglycemic activities in normal and in streptozotocin induced diabetic rats. Pharm Biol Eval 2(1):29–35

    Google Scholar 

  • Kurtz TW, Griffin KA, Bidani AK, et al. (2005) Recommendations for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 45:299–310

    Article  CAS  PubMed  Google Scholar 

  • Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39

    Article  CAS  PubMed  Google Scholar 

  • Lee KC, Chan CC, Yang YY, et al. (2013) Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One 8:1–11

    Article  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462

    Article  CAS  PubMed  Google Scholar 

  • Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, et al. (2008) Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118:984–993

    CAS  PubMed  PubMed Central  Google Scholar 

  • Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474

    Article  CAS  PubMed  Google Scholar 

  • Mehany HA, Abo-youssef AM, Ahmed LA, et al. (2013) Protective effect of vitamin E and atorvastatin againstpotassium dichromate-induced nephrotoxicity in rats. Beni-Suef Univ J Basic Appl Sci 2:96–102

    Article  Google Scholar 

  • Michel MC, Brunner HR, Foster C, Huo Y (2016) Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacol Ther in press

  • Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5:62–71

    Article  CAS  PubMed  Google Scholar 

  • Morgan T, Anderson A, Bertram D, MacInnis RJ (2004) Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin-Angiotensin-Aldosterone Syst 5:64–71

    Article  CAS  PubMed  Google Scholar 

  • Murray RL (1984) Creatinine. In: Kaplan LA, Pesce AJ (eds) Clinical chemistry; theory, analysis and correlation. CV Mosby Co., St. Louis, pp. 1247–1253

    Google Scholar 

  • Al-Harbi O Naif, Faisal Imam, Mohammed M Al-Harbi, Muzaffar Iqbal, Ahmed Nadeem (2014) Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. J Renin-Angiotensin Aldosterone Syst 1–8

  • O’brien RC, Luo M (1997) The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism 46:22–25

    Article  PubMed  Google Scholar 

  • Pagano PJ, Griswold MC, Ravel D, Cohen RA (1998) Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Diabetologia 41:9–15

    Article  CAS  PubMed  Google Scholar 

  • Pal PB, Sinha K, Sil PC (2014) Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFa related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One 9(9):e107220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Petrovas C, Daskas SM, Lianidou ES (1999) Determination of tumor necrosis factor-alpha (TNF-alpha) in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay. Clin Biochem 32(4):241–247

    Article  CAS  PubMed  Google Scholar 

  • Pilmore HL (2010) Metformin: potential benefits and use in chronic kidney disease. Nephrology 15:412–418

    Article  CAS  PubMed  Google Scholar 

  • Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, et al. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569–576

    Article  CAS  PubMed  Google Scholar 

  • Pushparaj PN, Low HK, Manikandan J, et al. (2007) Anti-diabetic effects of Cichoriumintybus in streptozotocin-induced diabetic rats. J Ethnopharmacol 111(2):430–434

    Article  CAS  PubMed  Google Scholar 

  • Rashikh A, Pillai KK, Ahmad SJ, et al. (2013) Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin-Angiotensin-Aldosterone Syst 14:14–22

    Article  CAS  PubMed  Google Scholar 

  • Satoh K (1978) Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 90(1):37–43

    Article  CAS  PubMed  Google Scholar 

  • Schernthaner G (2008) Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy. Nat Clin Pract Nephrol 4:656–657

    Article  CAS  PubMed  Google Scholar 

  • Sena CM, Louro T, Matafome P, et al. (2009) Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res 58:203–209

    CAS  PubMed  Google Scholar 

  • Sendecor GW, Cochran WG (1980) Statistical methods, 7th edn. Lowa State University, Ames

    Google Scholar 

  • Sheela N, Josem MA, Sathyamurthy D, Kumar BN (2013) Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats. IJKD 7(2):117–123

    PubMed  Google Scholar 

  • Shimoyama T, Yamaguchi S, Takahashi K, et al. (2006) Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metab Clin Exp 55:722–730

    Article  CAS  PubMed  Google Scholar 

  • Shlipak M (2011) Diabetic nephropathy: preventing progression. Br Med J Clin Evid Handb 83(6)

  • Sonta IT, Matsumoto S, et al. (2005) In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem Biophys Res Commun 330:415–422

    Article  CAS  PubMed  Google Scholar 

  • Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 22(2):158–161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaplan A Urea. In (1984) Kaplan LA, Pesce AJ: Clinicalchemistry: theory, analysis and correlation. St. Louis, Miss.: Mosby.437 (418): 1257–60

  • Vallejo S, Angulo J, Peiró C, et al. (2000) Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. J Diabetes Complicat 14:224–233

    Article  CAS  PubMed  Google Scholar 

  • Zhou G, Liu X, Cheung AK, Huang Y (2015) Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? Am J Transl Res 7(5):825–840

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for TGF beta as the major mediator. J Am Soc Nehrol 15:555–557 Nephropahty 2

    Google Scholar 

Download references

Contribution statement

HA and AM conceived and designed the study and conducted the systematic review. AM conducted the statistical analysis and drafted the paper. AM and LA contributed to interpreting the findings and revised the paper. NH, AS, and HA are involved in the critical revision of the paper. All authors edited and approved the final version of the manuscript to be published. AM had full access to data in the study and had final responsibility for the decision to submit for publication.

Author information

Authors and Affiliations

  1. Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, 35521, Egypt

    Amal M. Mahfoz & Nahed M. Hassanein

  2. Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt

    Amal M. Mahfoz

  3. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

    Hekma A. Abd El-Latif, Lamiaa A. Ahmed & Afaf A. Shoka

Authors
  1. Amal M. Mahfoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hekma A. Abd El-Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lamiaa A. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nahed M. Hassanein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Afaf A. Shoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amal M. Mahfoz.

Ethics declarations

Funding

No funding pursued for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahfoz, A.M., El-Latif, H.A.A., Ahmed, L.A. et al. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. Naunyn-Schmiedeberg's Arch Pharmacol 389, 1315–1324 (2016). https://doi.org/10.1007/s00210-016-1299-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-016-1299-2

Keywords

search

Navigation